ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: FR-PO516

Caffeine Consumption and Mortality in CKD

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 304 CKD: Epidemiology, Outcomes - Non-Cardiovascular


  • Bigotte Vieira, Miguel, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
  • Magriço, Rita, Hospital Garcia de Orta, Almada, Portugal
  • Viegas dias, Catarina, Dafundo Family Health Unit, Lisbon, Portugal
  • Leitão, Lia, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal
  • Neves, João Sérgio, São João Hospital, Faculty of Medicine, University of Porto, Portugal, Porto, Portugal

An inverse relationship between coffee consumption and mortality has been reported in the general population. However, the association between caffeine consumption and mortality in patients with CKD remains unclear.


We examined the association of caffeine consumption with mortality among 2328 patients with CKD (defined by estimated GFR < 60 mL/min/1.73m2, CKD-EPI) in a prospective nationwide cohort, using the continuous National Health and Nutrition Examination Survey (NHANES) 1999-2010. Caffeine consumption was assessed at baseline using 24-hour dietary recalls. Cox proportional hazard models were fitted to estimate hazard ratios (HR) for all-cause mortality according to quartiles of caffeine consumption, adjusting for potential confounders (age, gender, race, annual family income, education level, estimated GFR, albumin/creatinine ratio, hypertension, smoking status, dyslipidemia, body mass index, previous cardiovascular events and diet: consumption of alcohol, carbohydrates, polyunsaturated fatty acids and fibers). We assessed the extent to which CKD stage modified the effects of caffeine consumption on mortality with likelihood ratio tests for interaction.


Quartiles of caffeine consumption were: 1st quartile (<29.5 mg of caffeine/day), 2nd (30.5 to 101.0 mg/day), 3rd (101.5 to 206.0 mg/day), and 4th quartile (206.5 to 1378.5 mg/day). A dose-dependent inverse association between caffeine and all-cause mortality was observed in patients with CKD. Comparing with 1st quartile of caffeine consumption, adjusted HR for death was 0.88 (95% CI, 0.68-1.44) for 2nd quartile, 0.78 (95% CI, 0.60-1.01) for 3rd quartile and 0.76 (95% CI, 0.59-0.97) for 4th quartile (p=0.027 for trend across quartiles). There were no significant interactions between caffeine consumption quartiles and CKD stages with respect to all-cause mortality.


Our study showed a dose-dependent protective effect of caffeine consumption on mortality among patients with CKD.